

**Listing of Claims:**

1 – 5 (Cancelled)

6. (Currently Amended) A composition effective to neutralize CMV infection comprising CMV glycoprotein O polypeptide in combination with a pharmacologically acceptable carrier.

7. (Cancelled)

8. (Currently Amended) The composition of claim 6 wherein the polypeptide has a deletion of all or a portion of a transmembrane anchor region wherein the region consists of residues 1 – 30 of the CMV glycoprotein O sequence, SEQ ID NO:1

9. (Previously Amended) A method of treating a patient against CMV infection comprising administering the composition of claim 6 to the patient.

10. (Previously Amended) The method of claim 9 additionally comprising a step of administering at least one composition comprising at least a fragment of a glycoprotein selected from the group of CMV glycoprotein H, CMV glycoprotein L, and CMV glycoprotein B.

11. (Previously Amended) An anti-CMV drug comprising CMV glycoprotein O and a pharmacologically acceptable carrier.

Appl. No. 09/942,146  
Amdt. Dated November 18, 2004  
Reply to Office Action of May 18, 2004

12. (Original) The drug of claim 11 wherein the drug comprises full-length CMV glycoprotein O.

13 – 14 (Cancelled)